SSSW(SH:688399) Ge Long Hui A P P·2026-02-27 09:13Core Insights - The company, Shuoshi Biotechnology (688399.SH), reported a total operating revenue of 340.38 million yuan for the year 2025, reflecting a year-on-year decline of 2.64% [1] - The net profit attributable to the parent company was -39.71 million yuan, which represents an increase in losses by 37.71 million yuan compared to the previous year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -103.83 million yuan, with losses widening by 31.99 million yuan year-on-year [1] Business Performance - The company's main business showed stable development; however, it faced challenges due to intensified industry competition and ongoing medical procurement reforms [1] - The revenue from self-produced diagnostic reagent products decreased, partly due to an adjustment in the value-added tax rate to 13% [1] - The company is actively implementing cost reduction and efficiency enhancement measures, aiming to fully explore potential improvements in quality and efficiency [1] - It is expected that the overall gross profit margin will remain stable compared to the same period last year [1]